A Dose-Volume Study of a Treatment for Elevated IOP Due to Open-Angle Glaucoma or Ocular Hypertension

A Dose-Volume Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension

The purpose of this study was to assess the effects of total volume and total dose on the safety and intraocular pressure-lowering efficacy of Anecortave Acetate Suspension (3 mg and 48 mg) in 0.5 mL and 0.8 mL volumes when administered by anterior juxtascleral depot (AJD) for the treatment of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.

Inclusion Criteria:

• Clinical diagnosis of Open-Angle Glaucoma or Ocular Hypertension for at least 6 months;
• Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

• Prior angle surgery in the study eye, severe visual field loss in either eye;
• Other protocol-defined exclusion criteria may apply.